• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1261101 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
) x! y; x# h+ S4 K: tNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
4 k( n# v9 L9 d9 s+ Author Affiliations
" j5 f  q! T! {' m# ^
' x1 q5 ]  t) O# W* p+ \3 |: G1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ) ^8 J6 D6 ]0 X( R- p
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 5 i1 z6 Q, B/ \- n% |+ x8 g+ Q
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
7 c- N7 D# H0 d8 G# \9 ^' E; e4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan . \  C/ d8 M7 O0 _2 q7 y
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ) p( V9 T1 ?7 R0 O  H+ k6 d
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
; F; \& \6 I% U/ e: Z4 W* A4 \- M7Kinki University School of Medicine, Osaka 589-8511, Japan : ]8 q2 t* M# t2 F5 p0 e" K! h1 b
8Izumi Municipal Hospital, Osaka 594-0071, Japan
3 a/ Z3 j& K: r7 j- A( D7 n9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan   g" A( [; K2 P. }+ F; Q
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 6 f- L7 c% C% K
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 7 x6 G0 x9 Y  f8 {

4 S: p9 S* P5 v) N' a+ S
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
6 {- X+ L/ h& P. h1 t/ x$ l5 x9 z% B
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
% y+ V* S& X) U; q" b' \* o! x5 H0 Z4 e, }$ W+ }2 g( q
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
! c1 [0 A1 G- R" V4 c! n- N# U3 w9 z. K4 i6 b9 f
Published online on: Thursday, December 1, 2011
$ j0 @5 U* g0 D, j9 E( t) [7 j; U# F# M/ R3 ], P/ O
Doi: 10.3892/ol.2011.507
0 i/ B* n# C7 a% s6 w
0 `4 Z+ N) M% h7 h4 }: [$ tPages: 405-410 . R9 }7 k; u6 n- q

. [# g" J" L2 aAbstract:
9 Z: m8 `& i& TS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.; J. B1 H- T2 F) b( D  ?/ A
- M3 i, `1 s; |  i5 f; }
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population; y& R9 w4 U6 d* j, E8 R
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 9 M! |$ y5 U3 t6 X( v* ?; i. ?1 z
+ Author Affiliations7 s$ @. c- U7 _2 L! D5 K) w& k
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu 6 [/ U. {- g. v* S$ H" o- ^
2Department of Thoracic Surgery, Kyoto University, Kyoto
# ?* g- [2 w2 t, C$ T; U: O; P3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
3 J( i1 E& }* J$ \5 u( z&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
$ |* B7 w7 O0 `8 b9 g" o/ I* I0 yReceived September 3, 2010.
$ H& K: b" y2 J  s: BRevision received November 11, 2010.
2 o; M5 X* @2 A/ V" o  [Accepted November 17, 2010. & t* A# f, z5 w) a- W: o. K
Abstract" X! H+ ]+ [8 A  `: i, x& O
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
9 m3 R; ]5 e8 G* X2 wPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. ! U0 l9 x) N# G1 f% P( y* o
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. $ n; B: f# f; I! @0 E& l
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 7 V! S9 S, Y/ e+ L/ S
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。) C' ^3 b( B5 d- }8 U! s# O: q
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?, i1 Q4 T0 D# b& w( u/ o- q  Z
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
4 w" h; L# f: ?6 |2 ~" Ahttp://clinicaltrials.gov/ct2/show/NCT01523587
; O: [$ S& b8 ^1 I' S  G) K( y% r2 P! A9 u
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
2 X2 C- i0 T, q5 E1 o" `- rhttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 # {9 Y) J6 [! i* a5 ~6 _

8 P% W) T3 V: n从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。% R% [$ j# k+ ]4 `. e- R( \
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦

" L4 h8 p6 e6 j+ J$ ?$ C没有副作用是第一追求,效果显著是第二追求。& O% x9 x; g0 A. x
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表